Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review

Table 2 Targeted therapies to B-raf proto-oncogene serine/threonine kinase V600E in ameloblastomas

Ref.	Age	Evolu-tion tumor (yr)	Gender	Tumor	Locali-zation	Primary tumor/ recur-rent	Pre-vious treat-ments	Size	Course of the disea-ses	Muta-tion detected	Treat-ment	Evolu-tion	Follow-up
Kaye et al[27]	40	30	M	MA	Left jaw, bilateral neck mass, pulmo-nary metas-tases	Recurrent	Surgical resection and radiot-herapy	NS	Three recur-rences (13, 9, 7 yr), surgical resection (two recur-rences), RT (last recurrence), neck bilateral and lung metas-tasis. (imaging diagnosis CT)	BRAF V600E (gene profile and IHC)	BRAF/MEK inhibition (Dabra-fenib 150 mg twice daily + Trame-tinib 2 mg once daily)	Decrease of the tumor size and metas-tases in the first four days	20 wk (tumor response to treatment, without toxicity)
Faden et al[26]	83	16	F	AM	Right jaw	Recurrent	Conser-vative surgery	3.79 cm × 5.87 cm × 5.62 cm	Two recur-rences, difficult to nutrition, not suitable for surgery	BRAF V600E	Dabra-fenib 75 mg twice daily	Decrease of the tumor size	12 wk (tumor response to treatment)
Fernandes et al[29]	29	12	F	AM	Ramus and left jaw	Recurrent	Surgical resection and radiot-herapy	1.3 cm × 0.9 cm (residual tumor)	Tumor recur-rence by conser-vative surgery for 16 yr, metas-tases in cavernous sinus and tumorl extention to orbit	BRAF V600E (PCR allele-specific)	Vemurafenib 960 PO twice daily and analgesic treatment	Decrease of the tumor size with sympto-matology (anorexy, nausea and fatigue)	11 wk, asympto=matic with treatment tolerance
Tan et al[28]	85	NS	M	AM	Left jaw	Primary	Surgical resection	4 cm (CT Scan)	Tumor recur-rence with patho-logical fracture	BRAF V600E (PCR allele-specific)	Dabrafenib 150 mg PO twice daily	Decrea-sed of tumor size with develo-pment of actinic keratosis on face, back and scalp and thic-kening voice	16 wk, notable decrease of tumor size

NS: No specified; PO: Oral administration; BRAF: B-raf proto-oncogene serine/threonine kinase; IHC: Immunohistochemical; CT: Chemotherapy; MA: Metastatic ameloblastomas; AM: Ameloblastomas.